Published on 16 Sep 2022 on Zacks via Yahoo Finance
Integra LifeSciences Holdings Corporation IART has been gaining from continued sales growth across the Codman Specialty Surgical (CSS) and Tissue Technology segments. The company posted better-than-expected results in the second quarter of 2022. Robust demand for its products is encouraging. Integra’s continued focus on product innovation instills optimism. However, macroeconomic challenges and stiff competition raise apprehension.
In the past year, the Zacks Rank #3 (Hold) stock has declined 31.6% against the 31.2% fall of the industry. This compares with a 13.2% drop of the S&P 500.
The renowned medical device company has a market capitalization of $3.98 billion. Its second-quarter adjusted earnings per share surpassed the Zacks Consensus Estimate by 2.5%.